Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Roche Glycart AG focuses on the Biotechnology & Pharmaceuticals technology area. The company has 2 pending office actions currently active. These actions are handled by 2 distinct examiners and 2 distinct art units.
SKELDING, ZACHARY S is the busiest examiner, responsible for 1 pending office action. Since there are 2 pending office actions and 2 distinct examiners, each examiner is managing exactly 1 action. This means the workload is distributed across the 2 distinct examiners.
The involvement of 2 distinct art units suggests that the pending applications cover different technical sub-fields. Practitioners must manage 2 separate examiner relationships. With 2 pending office actions, the portfolio is in a low-volume phase. The lack of overlap between examiners means that each action should be treated as an independent matter. This distribution requires a strategy that accounts for different examiner preferences across the 2 distinct art units. The reliance on 2 distinct examiners, including SKELDING, ZACHARY S, ensures a diverse review process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKELDING, ZACHARY S | 1 | 59.8% | +41.3% |
| DAHLE, CHUN WU | 1 | 50.4% | +50.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18540730 | ANTIGEN BINDING MOLECULES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION | SKELDING, ZACHARY S | — |
| 18465037 | ANTIBODY FC VARIANTS | DAHLE, CHUN WU | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18540730 | ANTIGEN BINDING MOLECULES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION | SKELDING, ZACHARY S | 1644 | §103 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18465037 | ANTIBODY FC VARIANTS | DAHLE, CHUN WU | 1641 | §112Other | Non-Final OA | — | Pending | Sep 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRoche Glycart AG has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Zachary S Skelding has the most, with 1 of Roche Glycart AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.